|
1
|
Scheithauer W, Rosen H, Kornek GV, Sebesta
C and Depisch D: Randomised comparison of combination chemotherapy
plus supportive care with supportive care alone in patients with
metastatic colorectal cancer. BMJ. 306:752–755. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Thirion P, Michiels S, Pignon JP, et al:
Modulation of fluorouracil by leucovorin in patients with advanced
colorectal cancer: an updated meta-analysis. J Clin Oncol.
22:3766–3776. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
De Gramont A, Figer A, Seymour M, et al:
Leucovorin and fluorouracil with or without oxaliplatin as
first-line treatment in advanced colorectal cancer. J Clin Oncol.
18:2938–2947. 2000.
|
|
4
|
Giacchetti S, Perpoint B, Zidani R, et al:
Phase III multicenter randomized trial of oxaliplatin added to
chronomodulated fluorouracil-leucovorin as first-line treatment of
metastatic colorectal cancer. J Clin Oncol. 18:136–147. 2000.
|
|
5
|
Goldberg RM, Sargent DJ, Morton RF, et al:
Randomized controlled trial of reduced-dose bolus fluorouracil plus
leucovorin and irinotecan or infused fluorouracil plus leucovorin
and oxaliplatin in patients with previously untreated metastatic
colorectal cancer: a North American Intergroup Trial. J Clin Oncol.
24:3347–3353. 2006. View Article : Google Scholar
|
|
6
|
Shirasaka T, Nakano K, Takechi T, et al:
Antitumor activity of 1 M tegafur-0.4 M
5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against
human colon carcinoma orthotopically implanted into nude rats.
Cancer Res. 56:2602–2606. 1996.
|
|
7
|
Tatsumi K, Fukushima M, Shirasaka T and
Fujii S: Inhibitory effects of pyrimidine, barbituric acid and
pyridine derivatives on 5-fluorouracil degradation in rat liver
extracts. Jpn J Cancer Res. 78:748–755. 1987.PubMed/NCBI
|
|
8
|
Shirasaka T, Shimamato Y, Ohshimo H,
Yamaguchi M, Kato T, Yonekura K and Fukushima M: Development of a
novel form of an oral 5-fluorouracil derivative (S-1) directed to
the potentiation of the tumor selective cytotoxicity of
5-fluorouracil by two biochemical modulators. Anticancer Drugs.
7:548–557. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Sugimachi K, Maehara Y, Horikoshi N,
Shimada Y, Sakata Y, Mitachi Y and Taguchi T: An early phase II
study of oral S-1, a newly developed 5-fluorouracil derivative for
advanced and recurrent gastrointestinal cancers. The S-1
Gastrointestinal Cancer Study Group. Oncology. 57:202–210. 1999.
View Article : Google Scholar
|
|
10
|
Hoff PM, Saad ED, Ajani JA, et al: Phase I
study with pharmacokinetics of S-1 on an oral daily schedule for 28
days in patients with solid tumors. Clin Cancer Res. 9:134–142.
2003.PubMed/NCBI
|
|
11
|
Van Groeningen CJ, Peters GJ, Schornagel
JH, et al: Phase I clinical and pharmacokinetic study of oral S-1
in patients with advanced solid tumors. J Clin Oncol. 18:2772–2779.
2000.
|
|
12
|
Ohtsu A, Baba H, Sakata Y, Mitachi Y,
Horikoshi N, Sugimachi K and Taguchi T: Phase II study of S-1, a
novel oral fluoropyrimidine derivative, in patients with metastatic
colorectal carcinoma. S-1 Cooperative Colorectal Carcinoma Study
Group. Br J Cancer. 83:141–145. 2000.
|
|
13
|
Shirao K, Ohtsu A, Takada H, et al: Phase
II study of oral S-1 for treatment of metastatic colorectal
carcinoma. Cancer. 100:2355–2361. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Van den Brande J, Schöffski P, Schellens
JH, et al: EORTC Early Clinical Studies Group early phase II trial
of S-1 in patients with advanced or metastatic colorectal cancer.
Br J Cancer. 88:648–656. 2003.
|
|
15
|
Therasse P, Arbuck SG, Eisenhauer EA, et
al: New guidelines to evaluate the response to treatment in solid
tumors. European Organization for Research and Treatment of Cancer,
National Cancer Institute of the United States, National Cancer
Institute of Canada. J Natl Cancer Inst. 92:205–216. 2000.
View Article : Google Scholar
|
|
16
|
Cassidy J, Clarke S, Díaz-Rubio E, et al:
Randomized phase III study of capecitabine plus oxaliplatin
compared with fluorouracil/folinic acid plus oxaliplatin as
first-line therapy for metastatic colorectal cancer. Clin Oncol.
26:2006–2012. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rothenberg ML, Cox JV, Butts C, et al:
Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic
acid plus oxaliplatin (FOLFOX-4) as second-line therapy in
metastatic colorectal cancer: a randomized phase III noninferiority
study. Ann Oncol. 19:1720–1726. 2008. View Article : Google Scholar
|
|
18
|
Yamada Y, Hamaguchi T, Goto M, et al:
Plasma concentrations of 5-fluorouracil and F-alanine following
oral administration of S-1, a dihydropyrimidine dehydrogenase
inhibitory fluoropyrimidine, as compared with protracted venous
infusion of 5-fluorouracil. Br J Cancer. 89:816–820. 2003.
View Article : Google Scholar
|
|
19
|
Yamada Y, Tahara M, Miya T, et al: Phase
I/II study of oxaliplatin with oral S-1 as first-line therapy for
patients with metastatic colorectal cancer. Br J Cancer.
98:1034–1038. 2008. View Article : Google Scholar : PubMed/NCBI
|
